Opinion
Video
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Author(s):
Key Takeaways
- Germline testing for all prostate cancer patients may soon become standard, influencing urologists' testing protocols.
- Somatic testing is vital for identifying abnormalities in patients without germline mutations, enabling personalized treatment.
Sieber shares his thoughts on the potential for universal genetic testing to become a standard of care practice for patients with prostate cancer.
In this video, Paul Sieber, MD, shares his thoughts on what the future holds for genetic testing in prostate cancer. Sieber is the medical director for clinical trials at Keystone Urology Specialists in Lancaster, Pennsylvania.
Video Transcript:
Well, I'm glad you asked that question, because we just had an article that some other of my peers signed off on. It's going to go to the Journal of Clinical Oncology Practice talking about everybody with prostate cancer getting germline testing out of the gate. Everybody, everybody. Do I think it's going to happen? I think so. In fact, we've got this article accepted. I think [we're] going to see that coming. I think it's going to force urologists to say, "I have to test everybody." It's going to become the standard of care, hopefully, in the next couple of years. We'll see. And certainly somatic testing is equally important, because there's a lot of people who don't have germline abnormalities, but they have somatic abnormalities, which is going to tailor their treatment going forward.
This transcript was AI generated and edited by human editors for clarity.
